Huiyu Pharmaceutical(688553)2024-09-18 09:41Group 1: Company Overview - Huayu Pharmaceutical is a research-driven comprehensive pharmaceutical company focused on the development, production, and sales of oncology drugs and complex injectable drugs [2] - The company aims to provide effective, high-quality, and reasonably priced medications to global cancer patients, with a mission to make cancer a controllable disease [2] Group 2: Financial Performance - In the first half of 2024, the company achieved total revenue of CNY 532 million, an increase of 18.12% compared to the same period last year [2] - R&D investment amounted to CNY 159 million, slightly down from the previous year [2] - Net profit attributable to shareholders was CNY 65 million, a slight decrease, while net profit excluding non-operating gains and losses increased by 45.04% to CNY 43 million [2] Group 3: Sales and Market Expansion - Domestic sales revenue reached approximately CNY 448 million, a nearly 10% increase year-on-year, with 17 products generating sales [2][4] - The company’s marketing network covers over 2,000 hospitals across various provinces and regions in China [4] - International sales revenue was approximately CNY 64 million, a growth of 62.70% compared to the previous year, with products sold in 60 countries or regions [2][4] Group 4: Product Development and Pipeline - The company has submitted 4 new applications for quality generic drugs in the first half of 2024, bringing the total pending applications to 18, including 8 oncology drugs [3][4] - In the first half of 2024, 44 new registration applications were submitted overseas, with a total of 226 pending overseas applications [4] - The company is advancing 13 projects in the oncology treatment pipeline and other therapeutic areas [3][4] Group 5: Market Position and Competitiveness - According to data from Minet, the company ranked first in market share for injectable pemetrexed disodium and plerixafor in 2023, with other products like oxaliplatin and cytarabine ranking second [4] - The company plans to maintain high growth rates in overseas markets while continuing to advance innovative drug development in oncology [4]